Asparaginase Erwinia Chrysanthemi

Phase 3

Asparaginase Erwinia Chrysanthemi is one of 113 therapeutic programs targeting Acute Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecruiting

B Acute Lymphoblastic LeukemiaActive, not recruiting

Recurrent B Acute Lymphoblastic LeukemiaActive, not recruiting

Down SyndromeRecruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativePhase 2

Recruiting

B Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Recurrent B Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Down SyndromePhase 2

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 5

Vepesid

AAvyxa

Phase 3

52 6

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Cellcept

Busulfex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Recurrent B Acute Lymphoblastic Leukemia

NCT02981628

Q2 2027

Phase 3Active, not recruiting

Acute Myeloid Leukemia

NCT02521493

Q3 2027

Phase 3Active, not recruiting

B Acute Lymphoblastic Leukemia

NCT03914625

Q2 2028

Phase 1Recruiting

Recurrent B Acute Lymphoblastic Leukemia

NCT07133997

Phase 2Recruiting

Down Syndrome

NCT04546399

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

Recruiting·CChildren's Oncology Group·Phase 3·NCT04293562·1,400 enrolled

UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML: A Pilot Trial

Recruiting·JJoanna Yi·Phase 1·NCT07059975·36 enrolled

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT02521493·280 enrolled

Recurrent B Acute Lymphoblastic Leukemia2 trials

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Active, not recruiting·CChildren's Oncology Group·Phase 2·NCT02981628·80 enrolled

A Phase 1/1b Study Evaluating Asparaginase Erwinia Chrysanthemi- Recombinant-Rywn (Recombinant Erwinia Asparaginase) and Venetoclax in Combination With Blinatumomab in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Recruiting·CCity of Hope Medical Center·Phase 1·NCT07133997·26 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06317662·153 enrolled

Down syndrome1 trial

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04546399·461 enrolled

B Acute Lymphoblastic Leukemia1 trial

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03914625·6,720 enrolled

2 more indications

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1 trial

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia

Recruiting·UUniversity of Washington·Phase 2·NCT06738368·30 enrolled

Acute Lymphoblastic Leukemia1 trial

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Active, not recruiting·SSt. Jude Children's Research Hospital·Preclinical·NCT02553460·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Asparaginase Erwinia Chrysanthemi. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Asparaginase Erwinia Chrysanthemi. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSt. Jude Children's Research Hospital

Asparaginase Erwinia Chrysanthemi

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q2 2028

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Recurrent B Acute Lymphoblastic Leukemia2 trials

Acute Leukemia of Ambiguous Lineage1 trial

Down syndrome1 trial

B Acute Lymphoblastic Leukemia1 trial

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1 trial

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News